Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension
- 83 Downloads
Prevalence of hypertension (HTN) varies substantially across different populations. HTN is not only common – affecting at least one third of the world’s adult population – but is also the most important driver for cardiovascular diseases. Yet up to a third of hypertensive patients are resistant to therapy, contributed by secondary hypertension but more commonly the hitherto inability to precisely predict response to specific antihypertensive agents. Population and individual genomics information could be useful in guiding the selection and predicting the response to treatment – an approach known as precision medicine. However this cannot be achieved without the knowledge of genetic variations that influence blood pressure (BP). A number of evolutionary factors including population demographics and forces of natural selection may be involved. This article explores some ideas on how natural selection influences BP regulation in ethnically and geographically diverse populations that could lead to them being susceptible to HTN. We explore how such evolutionary factors could impact the implementation of precision medicine in HTN. Finally, in order to ensure the success of precision medicine in HTN, we call for more initiatives to understand the genetic architecture within and between diverse populations with ancestry from different parts of the world, and to precisely classify the intermediate phenotypes of HTN.
KeywordsHypertension Natural selection Precision medicine
Anatomical modern human
- Ang II
Genome-wide association study
Hypertension is a quantitative and multi-factorial trait. Hypertension (HTN) is defined as persistent elevation in BP greater than 140/90 mmHg . It is either primary (essential) or secondary whereby the former is not an outcome of other disorders such as endocrinopathies (eg: Conn’s syndrome, Phaeochromocytoma, acromegaly) or renal pathologies (eg: chronic glomerulonephritis, renal artery stenosis) where it would be classified as secondary HTN. Both situations may have substantial interplay between genetic and environmental factors.
The prevalence of HTN is on a steady rise today; yet up to a third of hypertensive individuals do not achieve the target BP despite being on multiple anti-hypertensive medications . Individuals with BP that is persistently above goals despite the use of three anti-hypertensives at optimum doses are categorized as having “drug-resistant hypertension (DRH)” . Ethnic variations in BPs and differences in response to anti-hypertensive therapies though, have been well recognized [4, 5]. Numerous factors have been invoked to explain DRH: non-compliance to medications, age, gender, circadian rhythm, individual lifestyle and physical activity, the inability to prescribe an appropriate specific anti-hypertensive treatment due to the inability to predict the efficacy of the drug in a specific individual [6, 7], genetic background of an individual, and genetic variability between individuals [3, 8]. New drug development may address this issue, but it may not necessarily be individualized. Genetic basis of population and individual variation that may contribute to DRH could be the key and which would shape precision medicine and its future. However this cannot be achieved without knowing the genetic ‘fingerprints’ that are responsible for the development and maintenance of HTN in individuals with varied genetic make-up.
This article reviews the possible primordial cause(s) of HTN by revisiting the evolutionary process of BP regulation and the impact of natural selection and local adaptation of anatomical modern human (AMH) to the variability of BP. We also explore the possible impact afforded by genetic variability to precision medicine in HTN.
Molecular and physiological mechanisms of BP regulation
Evolution and natural selection of BP in human survival
Natural selection is the key driving force for all evolutionary and adaptation processes. It is a process to improve the fitness of reproduction against environmental exposure by preserving the beneficial traits and discarding unfavourable ones. In other words, alleles that express traits with better adaptation capability will tend to increase in frequencies over generations and be preserved in a population; whilst alleles that express unfavourable traits decrease in frequencies. Nonetheless every trait under natural selection often has a trade-off – a negative trait may be favourable in another circumstance. A typical model is exemplified by the HbS mutation which causes sickle cell anaemia on one hand but is selectively advantageous against severe malaria infection on the other.
(i) Increased systemic BP for a sustained physical performance:
The hunting-gathering lifestyle of the ancestors of AMH requires high physical stamina and endurance as they ran on an average of approximately 35 km in 2–5 h . Essentially, smaller capillary diameters but denser capillarization increases the effectiveness of O2 exchange [19, 23], thereby increasing sustained aerobic activity which can maintain high physical performance. As compensation to the physiological adaptation, systemic BP is elevated to maintain sufficient blood flow in the circulation that could withstand the high capillary resistance generated from smaller capillary diameter. Whilst it has been proven true in cross-species studies , this hypothesis is also supported by the observation that athletes and physically active individuals generally have higher BP than those with sedentary lifestyles .
(ii) Heat adaptation, water and sodium retention:
Tropical climate and hunting-gathering lifestyle require effective heat dissipation via excessive sweat loss as proposed by previous studies which reported as much as 2 L/hour of sweat loss under these conditions [25, 26]. The resultant excessive sweat loss leads to unavoidable sodium loss and therefore disruption of fluid homeostasis that can affect muscle contraction, nerve impulse, glucose absorption and several other metabolic functions within the cells, which if persistent, could result in heart failure [18, 27, 28]. Given the critical importance of salt to human survival, natural selection could have been driven to prefer salt-avidity genetic variations, yet able to lose heat effectively . In contrast, decreased blood volume due to fluid loss could exert increased stress on the cardiovascular system due to increased cardiac contractility to increase blood flow to the skin as a cooling down mechanism. Consequently, physical performance declined.
(iii) Energy metabolism and ‘Thrifty Gene’ hypotheses:
Low energy intake of the hunter-gatherers during Pleistocene period often led to extreme stress of starvation. During periods of prolonged starvation, BP drops in proportion to the significant reduction in available energy. In response, arterial tone and force of cardiac contraction increased in order to maintain BP and ensure organ perfusion [18, 26, 29]. Therefore, genetic variation that enhances arterial and cardiac contractility, as well as those of energy-preservation advantage, might have conferred survival advantage in the environmental context of early AMH evolution, which in turn led to increased BP as a counter balance.
In addition, it has been postulated that low energy intake and malnutrition in mothers could affect the embryo development and foetus health via altering or silencing gene expressions related to energy metabolism pathways in order to cope with famine, e.g. foetal cardiac gene programme switches the energy metabolism of the heart from fatty acid oxidation to glycolysis . In modern lifestyle, the deprived adapted foetus lives in a nutrient rich environment postnatally, the physiological changes that were prevalent prenatally are detrimental, which in part could potentially increase the risk of elevated BP .
(iv) The Slavery Hypothesis:
The Slavery Hypothesis is one of the commonly accepted hypothesis that explains the high incidence of HTN and cardiovascular diseases (CVD) among the African Americans . This hypothesis proposes that the African Americans possess increased risk of HTN and CVD as a consequence of strong selection during the period of ‘Middle Passage’ and enslavement. Historical records showed that large numbers of captive Africans who were shipped to the North America via the Atlantic Ocean died either during the journey, or soon upon arrival, due to poor living conditions which included dehydration, malnutrition, infectious diseases. The acute drop in numbers of enslaved Africans in North America resulted in a severe genetic bottleneck. Those that survived however, are likely to carry the ancestral variants (defined by allele that was carried by the common ancestor of the taxon, presumably chimpanzee as the outgroup species closest to human) with excess frequencies as a result of attempts to rapidly adapt to the extreme stress of dehydration.
(iv) Chronic infections:
Ancestors of AMH have been exposed to various infections, primarily attributed to their primitive life of hunting and gathering which exposed them to various pathogens. Several recent reports have attributed elevated BP to a number of infectious diseases, notably cytomegalovirus, periodontal bacteria and plasmodium sp. [33, 34, 35, 36, 37]. It was postulated that chronic exposure to these infections could have either triggered the pro-inflammatory cascade, or conferred oxidative stress to the circulation, thus enhancing the renin-angiotensin-aldosterone system (RAAS) which in turn elevated the BP .
Collectively, the genomic structure of ancestral AMH was shaped in a way that the ancestral alleles of the selected genes were better preserved and adapted to a resource-deficient environment. As the ancestors of AMH trekked across the savannah and inhabited other parts of the world, the snail-speed process of evolution could not cope with the rapidly changing climate and civilization. The selective advantage traits/variations, which in this case is elevated BP, has suddenly become a burden to the new lifestyles of improved hygiene conditions, enriched and increased food resources and sedentary lifestyle . These hypotheses continued to be debated, with some claiming supportive evidence while others requiring further investigations. Herewith, we summarize several lines of findings that support these hypotheses.
From the epidemiological perspective, despite well recorded higher prevalence of HTN and CVD among the African Americans, numerous studies consistently noted that African populations (e.g Pygmy Bantu) have generally higher BP than the non-African populations . Several other populations of African ancestry, such as the Haitian Black, the French Caribbean region of Martinique, French Guyana, and Guadeloupe [39, 40], or populations of phenotypically similar to the Africans (or often categorized as Negritos by anthropologists) such as the aboriginal populations from Australia, and indigenous Negrito populations from Peninsular Malaysia who are known to be hunter-gatherers, have been reported to have higher levels of BP than their counterparts in the non-indigenous population [41, 42]. This though intriguingly not seen among the hunter-gatherers from Europe . Whilst general consensus to these observations is that socio-economy, lifestyles, education and awareness are the major contributing factors, the plausibility of population demographic and genetic architecture of these populations to BP elevation should not be disregarded.
HTN has been linked to malarial infection via several indirect mechanisms including malnutrition of pregnant mothers and foetus, as well as chronic inflammation. One significant supporting example is, females in regions with malaria hyper-endemicity are likely to have acquired immunity to prevent most febrile episodes, thus suffer impaired uteroplancental blood flow and maternal anaemia, which leads to foetal growth restriction subsequently low birth weight [34, 48]. Febrile malaria episodes that are more likely among women with low immunity are thought to induce uterine contractions, which are mediated by elevated levels of tumour necrosis factor-α (TNF α) leading to preterm birth [34, 49]; whilst Gallego-Delgado and Rodriquez provided supporting information that angiotensin II (Ang II) may protect against cerebral malaria, possibly via its effects on host vascular endothelial cells . A candidate gene CDH13 that was associated with HTN in a handful of GWAS [51, 52, 53, 54], interestingly noted that it was also found to be significantly associated with susceptibility to malarial infection in a meta-GWAS analysis [55, 56]. Recent search revealed CDH13 was one of the most prominent signals for positive natural selection in the Negrito populations from Peninsular Malaysia [57, 58]. Malaria threat among the Negritos has long been recorded [59, 60]; at the same time, more than half of this population are hypertensive . Given the phenotypic observation and the fundamental role of this gene, it is plausible to postulate CDH13 as a target of natural selection for malaria and HTN. However, we acknowledge that a direct correlation between malaria infection and blood pressure alteration is yet to be conclusively established, thus providing an insight on the direction of the selection pressure for this gene. In contrast, infection with cytomegalovirus enhances renin and Ang II activities, which in turn triggers RAAS, subsequently elevating BP [33, 61], may imply the complexity of the biology of BP regulation and infectious disease.
The implications of evolutionary genetics to pharmacogenomics and precision medicine in HTN
Identifying and prioritizing HTN associated causal variants between and within populations:
We acknowledge that the genetic landscape of HTN is largely influenced by evolutionary forces such as natural selection and local adaptation. Ideally, candidate gene variant(s) under selective pressure are often functionally important to BP regulation. Surprisingly several variants that were functionally validated including rs699/rs5051 (AGT gene); rs5443 (GNB3 gene) and rs4293393 (UMOD gene), which were thought to be suitable candidates, however, yielded contrasting results in association with BP in different populations [8, 15, 25, 65]. One postulation is that selection process of these functional variants could have taken place long time ago, and has reached a fixation stage across populations .
However, a recent search on GWAS catalogue (https://www.ebi.ac.uk/gwas/) (using keywords ‘blood pressure’ and ‘hypertension’; date 11th February 2018) revealed as many as 457 GWAS signals that reached the genome-wide significant threshold at p < 10− 7, of which 283 were distinct, corresponding to 245 candidate genes (Additional file 1: Table S1). Moreover, only 7 candidate genes with established pathophysiological mechanisms of HTN were replicated in GWAS (ACE1, ACE2, ADRB1, ADRB2, MME, CACNA2D2 and UMOD). These observations imply that (i) the genetic variants underlying HTN are relatively common (occurring > 1% in a population), have undergone little or no selection in earlier populations, and mutations (derived alleles) could have occurred before or during early AMH migration out-of-Africa; (ii) the physiology of HTN is probably more complex and heterogeneous than our current understanding;(iii) it remains a challenge to identify which genetic marker (or array of genetic markers) best suits the pharmacogenomics approach in HTN.
Some encouraging progress has been seen albeit at a preliminary stage. For instance, a clinical trial was carried out to predict the investigating the response of diuretics on HTN patients who carried UMOD rs13333226-AA genotype  found that HTN individuals with the said genotype had increased UMOD excretion, thus greater salt sensitivity [67, 68, 69]. According to Dominiczak et al. (2017), a prospective UMOD rs13333226-AA genotype directed trial of a long-acting loop diuretic, torasemide, in uncontrolled hypertensive is currently ongoing . Whereas two clinical trials, namely the Nordic Diltiazem (NORDIL) and Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies, applied the NEDD4L rs4149601 genotype to predict the response of HTN patients on thiazide diuretics [70, 71]. The rs4149601 G-variant creates a cryptic splice site in NEDD4L, which leads to less ENaC downregulation, thereby increased sodium retention. The NORDIL study claimed that the HTN individuals carrying the G allele showed better response to the thiazide/β-blocker treatment compared to those with AA genotype ; whereas in PEAR study, the rs4149601 G allele showed better response to hydrochlorothiazide but no difference by genotype in response to the β-blocker atenolol .
The solution to this challenge however, relies on understanding the genetic architecture within and between a wide range of populations with ancestry from different parts of the world [73, 74]. In other words, cataloguing genomic variations that cover diverse populations, especially the indigenous populations are crucial to ensure the success of personalized medicine.
Identifying the intermediate phenotypes of HTN:
The findings from GWAS imply that the pathophysiology of HTN is heterogeneous, thus in agreement with the postulations that multiple causative factors which interplay with different environment factors could have contributed to the elevation of BP in different populations. Therefore characterizing different intermediate phenotypes of HTN is crucial [7, 75, 76, 77]. Korner (2010) defined two major intermediate phenotypes of HTN – stress and salt-sensitive HTN and obesity related HTN, which could be further characterized by neural and non-neural mechanisms . In addition, it was recognized earlier that there are two distinct physiological salt-sensitive HTN namely, the non-modulating salt-sensitive and the low renin salt sensitive . Another intermediate phenotype of HTN has been recognized as the neurogenic HTN namely the deoxycorticosterone acetate (DOCA) salt hypertension, which exhibits salt-dependent of excess mineralocorticoid [12, 78].
Disease heterogeneity is the major source of variability in response to anti-HTN medication . Precise ‘phenotyping’ therefore, is the key to identifying the causative gene(s) or variant(s) of HTN thus warrant the long-term success of pharmacogenomics and precision medicine. Several evolutionary drivers elaborated in this article may be able to shed lights to attempts of identifying different intermediate phenotypes for HTN. However, more efforts are required to comprehensively understand the physiology of HTN to categorize the disease phenotypes.
The concept of precision medicine may seem far-fetched at present. But looking back when the idea of going to the moon seemed impossible, man had taken this figment of imagination and realized it. The development of science and technology, particularly in the area of pharmacogenomics, has pointed us in the right direction though the journey remains long before we can even begin to consider personalized medicine. However, with future research advances, one day, precision medicine will no longer be a notion, but a reality and a way forward in medicine. But this can only be achieved with a comprehensive understanding on the complex ‘genotype-phenotype’ interactions.
Forces of evolution and natural selection could have resulted in variability in BP across global populations with diverse ancestry, which could have possibly led to different pathophysiological mechanisms or intermediate phenotypes of HTN. This in part resulted in different responses towards anti-HTN medications today. Whilst the Life Sciences community believes that the advancement of the genome sequencing and ‘-omics’ technology could provide a solution to the precision medicine in HTN, equally important is the identification of intermediate phenotypes of HTN (and its related biochemical traits); and the crucial cataloguing of both rare and common variants of various populations as reference to better understand the evolution of common traits like HTN, and how these variants found in different parts of the world influence HTN and its response towards medications.
B.P.H acknowledges the Chinese Academy of Sciences President’s International Fellowship Initiatives (2017VBA0008) awarded to him. Y.K. is supported by the Ministry of Higher Education Malaysia under Long Term Research Grant Scheme [Grant code: 600-RMI/LRGS 5/3 (2/2011)-2]; B.P.H thank the Ministry of Higher Education Fundamental Research Grant Scheme [Grant code: FRGS/1/2015/ST03/UCSI/01/1] for supporting part of the data analysis in this article.
Chinese Academy of Sciences President’s International Fellowship Initiatives (2017VBA0008).
Ministry of Higher Education Malaysia under Long Term Research Grant Scheme [Grant code: 600-RMI/LRGS 5/3 (2/2011)-2].
Ministry of Higher Education Fundamental Research Grant Scheme [Grant code: FRGS/1/2015/ST03/UCSI/01/1].
Availability of data and materials
BPH conceptualized the manuscript. YK and TAR provided their input to the manuscript from clinical perspective. All authors contributed to the writing, and have read and approved the manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 16.Mattson DL, Liang M. Hypertension: from GWAS to functional genomics-based precision medicine. Nat Rev Nephrol. 2017. https://doi.org/10.1038/nrneph.2017.21.
- 22.Denton DA. The hunger for salt : an anthropological, physiological, and medical analysis. Springer Berlin Heidelberg; 1982.Google Scholar
- 28.Yatabe MS, Yatabe J, Yoneda M, Watanabe T, Otsuki M, Felder RA, et al. Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. Am J Clin Nutr. 2010;92:77–82.CrossRefGoogle Scholar
- 33.Wall NA, Chue CD, Edwards NC, Pankhurst T, Harper L, Steeds RP, et al. Cytomegalovirus Seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. PLoS One. 2013;8:1–7.Google Scholar
- 35.Li C, Samaranayake NR, Ong KL, Wong HK, Cheung BMY. Is human cytomegalovirus infection associated with hypertension? The United States national health and nutrition examination survey 1999-2002. PLoS One. 2012;7:1999–2002.Google Scholar
- 49.Aidoo M, McElroy PD, Kolczak MS, Terlouw DJ, ter Kuile FO, Nahlen B, et al. Tumor necrosis factor-α promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo bay cohort project IX. Genet Epidemiol. 2001;21:201–11.CrossRefGoogle Scholar
- 54.Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017. https://doi.org/10.1038/ng.3768.
- 55.Band G, Le QS, Jostins L, Pirinen M, Kivinen K, Jallow M, et al. Imputation-Based Meta-Analysis of Severe Malaria in Three African Populations. PLoS Genet. 9(5):e1003509. https://doi.org/10.1371/journal.pgen.1003509.
- 60.Baer AS, Concerns C for OA. Health, disease, and survival : a biomedical and genetic analysis of the orang Asli of Malaysia. 1st ed. Subang Jaya: Center for Orang Asli Concerns, Subang Jaya, Malaysia; 1999.Google Scholar
- 61.Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009;5.Google Scholar
- 63.Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A. Medical Genetics Summaries. Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Natl. Cent. Biotechnol. Inf. Bethesda: National Center for Biotechnology Information (US), Bethesda (MD) All; 2018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28520346.
- 65.Furusawa T, Naka I, Yamauchi T, Natsuhara K, Eddie R, Kimura R, et al. Hypertension-susceptibility gene prevalence in the Pacific Islands and associations with hypertension in Melanesia. J Hum Genet. 2013;58(3):142-9.Google Scholar
- 66.Jobling M, Hollox E, Kivisild T, Tyler-Smith C. Human evolutionary genetics. Garl Sci. 2014.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.